Cargando…
The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment
Pediatric Adamantinomatous Craniopharyngiomas (ACPs) are histologically benign brain tumors that often follow an aggressive clinical course. Their suprasellar location leaves them in close proximity to critical neurological and vascular structures and often results in significant neuroendocrine morb...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074265/ https://www.ncbi.nlm.nih.gov/pubmed/32075140 http://dx.doi.org/10.3390/jcm9020519 |
_version_ | 1783506793848111104 |
---|---|
author | Whelan, Ros Prince, Eric Gilani, Ahmed Hankinson, Todd |
author_facet | Whelan, Ros Prince, Eric Gilani, Ahmed Hankinson, Todd |
author_sort | Whelan, Ros |
collection | PubMed |
description | Pediatric Adamantinomatous Craniopharyngiomas (ACPs) are histologically benign brain tumors that often follow an aggressive clinical course. Their suprasellar location leaves them in close proximity to critical neurological and vascular structures and often results in significant neuroendocrine morbidity. Current treatment paradigms, involving surgical resection and radiotherapy, confer significant morbidity to patients and there is an obvious need to discover effective and safe alternative treatments. Recent years have witnessed significant efforts to fully detail the genomic, transcriptomic and proteomic make-up of these tumors, in an attempt to identify potential therapeutic targets. These studies have resulted in ever mounting evidence that inflammatory processes and the immune response play a critical role in the pathogenesis of both the solid and cystic portion of ACPs. Several inflammatory and immune markers have been identified in both the cyst fluid and solid tumor tissue of ACP. Due to the existence of effective agents that target them, IL-6 and immune checkpoint inhibitors seem to present the most likely immediate candidates for clinical trials of targeted immune-related therapy in ACP. If effective, such agents may result in a paradigm shift in treatment that ultimately reduces morbidity and results in better outcomes for our patients. |
format | Online Article Text |
id | pubmed-7074265 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70742652020-03-19 The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment Whelan, Ros Prince, Eric Gilani, Ahmed Hankinson, Todd J Clin Med Review Pediatric Adamantinomatous Craniopharyngiomas (ACPs) are histologically benign brain tumors that often follow an aggressive clinical course. Their suprasellar location leaves them in close proximity to critical neurological and vascular structures and often results in significant neuroendocrine morbidity. Current treatment paradigms, involving surgical resection and radiotherapy, confer significant morbidity to patients and there is an obvious need to discover effective and safe alternative treatments. Recent years have witnessed significant efforts to fully detail the genomic, transcriptomic and proteomic make-up of these tumors, in an attempt to identify potential therapeutic targets. These studies have resulted in ever mounting evidence that inflammatory processes and the immune response play a critical role in the pathogenesis of both the solid and cystic portion of ACPs. Several inflammatory and immune markers have been identified in both the cyst fluid and solid tumor tissue of ACP. Due to the existence of effective agents that target them, IL-6 and immune checkpoint inhibitors seem to present the most likely immediate candidates for clinical trials of targeted immune-related therapy in ACP. If effective, such agents may result in a paradigm shift in treatment that ultimately reduces morbidity and results in better outcomes for our patients. MDPI 2020-02-14 /pmc/articles/PMC7074265/ /pubmed/32075140 http://dx.doi.org/10.3390/jcm9020519 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Whelan, Ros Prince, Eric Gilani, Ahmed Hankinson, Todd The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment |
title | The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment |
title_full | The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment |
title_fullStr | The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment |
title_full_unstemmed | The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment |
title_short | The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment |
title_sort | inflammatory milieu of adamantinomatous craniopharyngioma and its implications for treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074265/ https://www.ncbi.nlm.nih.gov/pubmed/32075140 http://dx.doi.org/10.3390/jcm9020519 |
work_keys_str_mv | AT whelanros theinflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment AT princeeric theinflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment AT gilaniahmed theinflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment AT hankinsontodd theinflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment AT whelanros inflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment AT princeeric inflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment AT gilaniahmed inflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment AT hankinsontodd inflammatorymilieuofadamantinomatouscraniopharyngiomaanditsimplicationsfortreatment |